|U.S. Vaginal Sling, Benign Prostatic Hyperplasia Device and Prostate Cancer ...|
While some formerly high-growth segments, including vaginal slings, benign prostatic hyperplasia (BPH) treatment devices and prostate cancer treatment devices, declined in 2013, various factors will fuel a rebound in these markets in the years ahead.
PR Newswire (press release) - Tue, 04 Mar 2014 07:02
|Psychosocial outcomes related to severity of congenital adrenal hyperplasia|
Varying psychosocial outcomes may be related to the clinical severity of congenital adrenal hyperplasia, according to data published in the Journal of Clinical Endocrinology and Metabolism. Congenital adrenal hyperplasia (CAH) — a deficiency of ...
Healio - Thu, 27 Feb 2014 08:30
|Same Cancer Risk With Two Breast Atypias|
A type of breast hyperplasia previously dismissed as a direct cancer precursor preceded invasive breast cancer just as often as a more ominous type of hyperplasia, according to long-term follow-up of 700 women. Both atypical ductal hyperplasia (ADH ...
MedPage Today - Wed, 05 Feb 2014 13:34
|Two types of breast tissue abnormalities equally likely to progress to cancer|
Both atypical ductal hyperplasia and atypical lobular hyperplasia should be considered premalignant lesions with equal potential of progression to breast cancer, according to study results. The findings contradict the current clinical understanding ...
Healio - Thu, 27 Feb 2014 03:15
|Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on ...|
The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the ...
MarketWatch - Thu, 06 Mar 2014 07:22
|Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and ...|
SYS-CON Media (press release) - Thu, 06 Mar 2014 05:30
|NxThera Raises More Than $25M in Series C Round for Minimally Invasive BPH ...|
NxThera Inc. has raised more than $25 million in a Series C financing designed to fund it to U.S. marketing authorization of a minimally invasive treatment for benign prostatic hyperplasia. Benign prostatic hyperplasia, or BPH, is a noncancerous ...
Dow Jones Bankruptcy & Debt (registration) - Wed, 26 Feb 2014 16:33
|NxThera Announces Completion of Series C Financing|
The Herald | HeraldOnline.com (press release) - Wed, 26 Feb 2014 11:41
|New data contradicts current recommendations for managing breast biopsy ...|
This study challenges current understanding that atypical ductal hyperplasia (ADH), a type of breast tissue abnormality, leads to breast cancer in the same breast while atypical lobular hyperplasia (ALH), another type of breast tissue abnormality, may ...
Oncology Nurse Advisor - Thu, 13 Feb 2014 07:53
|Doctor aiming for hair loss therapy breakthrough for women|
Propecia (finasteride) is a pill developed to treat an enlarged prostate (benign prostatic hyperplasia or BPH) in men, that was then found to stop hair loss and promote hair growth. Women were warned away initially, especially women who might get ...
Palm Beach Daily News - Thu, 06 Mar 2014 21:14